43792 Treatment Outcomes for up to 2 Years in Patients Aged Less Than 12 Years with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis: Real-World Data From PEDISTAD

Background: In phase-3 studies, dupilumab significantly improved disease severity in patients with moderate-to-severe atopic dermatitis (AD); however, less is known about the impact of systemic treatments on children in real-world treatment settings.